



## **Sortilin in Glucose Homeostasis: From Accessory Protein to Key Player?**

Nicolas Blondeau, Sophie Béraud-Dufour, Patricia Lebrun, Céline Hivelin, Thierry Coppola

### **► To cite this version:**

Nicolas Blondeau, Sophie Béraud-Dufour, Patricia Lebrun, Céline Hivelin, Thierry Coppola. Sortilin in Glucose Homeostasis: From Accessory Protein to Key Player?. *Frontiers in Pharmacology*, 2019, 9, <10.3389/fphar.2018.01561>. <hal-02265199>

**HAL Id: hal-02265199**

**<https://hal.science/hal-02265199v1>**

Submitted on 5 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC-ND 4.0 - Attribution - Non-commercial use - No Derivative Works - International License



# Sortilin in Glucose Homeostasis: From Accessory Protein to Key Player?

Nicolas Blondeau<sup>†</sup>, Sophie Béraud-Dufour<sup>†</sup>, Patricia Lebrun, Céline Hivelin and Thierry Coppola\*

Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Université Côte d'Azur, Valbonne, France

## OPEN ACCESS

### Edited by:

Salvatore Salomone,  
Università degli Studi di Catania, Italy

### Reviewed by:

Marcia Hiriart,  
Instituto de Fisiología Celular (IFC),  
Mexico  
Jiri Jiracek,  
Institute of Organic Chemistry  
and Biochemistry (ASCR), Czechia

### \*Correspondence:

Thierry Coppola  
coppola@ipmc.cnrs.fr

<sup>†</sup> These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Experimental Pharmacology  
and Drug Discovery,  
a section of the journal  
Frontiers in Pharmacology

**Received:** 20 September 2018

**Accepted:** 21 December 2018

**Published:** 15 January 2019

### Citation:

Blondeau N, Béraud-Dufour S,  
Lebrun P, Hivelin C and Coppola T  
(2019) Sortilin in Glucose  
Homeostasis: From Accessory  
Protein to Key Player?  
*Front. Pharmacol.* 9:1561.  
doi: 10.3389/fphar.2018.01561

The pharmacological properties and physiological roles of the type I receptor sortilin, also called neurotensin receptor-3, are various and complex. Sortilin is involved in important biological functions from neurotensin and pro-Nerve Growth Factor signaling in the central nervous system to regulation of glucose and lipid homeostasis in the periphery. The peripheral functions of sortilin being less extensively addressed, the focus of the current review is to discuss recent works describing sortilin-induced molecular mechanisms regulating blood glucose homeostasis and insulin signaling. Thus, an overview of several roles ascribed to sortilin in diabetes and other metabolic diseases are presented. Investigations on crucial cellular pathways involved in the protective effect of sortilin receptor on beta cells, including recent discoveries about regulation of cell fate, are also detailed. In addition, we provide a special focus on insulin secretion regulation involving complexes between sortilin and neurotensin receptors. The last section comments on the future research areas which should be developed to address the function of new effectors of the sortilin system in the endocrine apparatus.

**Keywords:** diabetes, receptor, pharmacology, signaling, physiology

## SORTILIN RECEPTOR


The protein sortilin, composed of 833 amino acids in human, is a high affinity receptor ( $K_d \approx 0.3$  nM) for NT (Mazella et al., 1989, 1998). It was first identified in 1997 as a receptor-associated protein (RAP) (Petersen et al., 1997). Sortilin belongs to the Vps10p family of type I receptors, with SorLA and SorCS1-3 receptors (Jacobsen et al., 1996; Hermey et al., 1999). The members of this family are characterized by a single transmembrane domain framed by an extracellular domain rich in cysteines (comparable to that of the Vps10p trivalent vacuolar protein of yeast), and a short intracellular end (C-terminal domain) involved in its internalization (Petersen et al., 1996, 1997; Mazella et al., 1998). Sortilin is widely expressed in the central nervous system, particularly in the hippocampus, dentate gyrus and cerebral cortex (Hermans-Borgmeyer et al., 1999). It is also present in the spinal cord, skeletal muscle, testes, heart, placenta, pancreas, prostate, and small intestine

**Abbreviations:** AKT, RAC-alpha serine/threonine-protein kinase; BDNF, brain derived neurotrophic factor; DIO, diet induced obesity; ERK, extracellular signal-regulated kinases; GPCR, G protein coupled receptor; IPGTT, intra peritoneal glucose tolerance test;  $K_2P$ , two-pore-domain background potassium channel; Ldlr, low-density lipoprotein receptor; NGF, nerve growth factor; NT, neurotensin; NTSR2, neurotensin receptor-2; NTSR3, neurotensin receptor-3; p75NTR, neurotrophin receptor of 75 kDa; PKC, protein kinase C; PM, plasma membrane; STZ, streptozotocin.

(Petersen et al., 1997). Sortilin distribution in the cell is highly regulated. While it is very poorly present at the PM (5–10%), the bulk of the protein localizes in intracellular compartments (vesicles and trans-golgi network) (Morris et al., 1998). If three NT receptors (NTSRs) NTSR1, NTSR2 and NTSR3 (or sortilin) mediate the effects of NT, the NTSR1 and NTSR2 receptors belong to the large GPCR (G Protein-Coupled Receptor) family in contrast to sortilin that is a sorting receptor with a single transmembrane domain (Mazella et al., 1989, 1998).

Sortilin is synthesized in an immature form, prosortilin. Prosortilin conversion to its mature receptor occurs in the Golgi apparatus through removal of its N terminal domain by the pro-convertase furin. This leads to the release of a peptide of 44 amino acids (SDP for sortilin derived propeptide: Gln1-Arg44, also known as PE). While such maturation process is a general mechanism to control receptor or enzyme activation, in the present case, the canonical furin cleavage leads also to the release of a new active peptide. Indeed, SDP binds to mature sortilin and TREK-1 channel with a high affinity ( $K_d \sim 5nM$ ) (Munck Petersen et al., 1999; Mazella et al., 2010). Several groups have also largely documented that sortilin is a co-receptor of the prodomain of proNGF and proBDNF (Nykjaer et al., 2004; Teng et al., 2005; Arnett et al., 2007).

Even though the binding properties of each sortilin ligand have not been clearly unraveled, data suggest that binding sites are similar for most of them (Quistgaard et al., 2009).



**FIGURE 1 |** Sortilin structural model. Sortilin complexed with NT structural model PDB 3F6K. The extracellular domain of sortilin, receptor for NT was crystallized and the tridimensional structure at 2Å resolution was determined. Peptides binding (two sites) relates to the restricted space inside the tunnel of the  $\beta$ -propeller (Quistgaard et al., 2009, 2014). Sortilin is shown in gray and NT in red.

As illustrated by **Figure 1**, NT (in red) binds to sortilin (in gray) in a tunnel of a ten-bladed  $\beta$ -propeller domain. The structural properties of sortilin suggests that NT is completely contained inside the tunnel of the  $\beta$ -propeller, firmly bound by its C-terminus and further attached by its N-terminal part at a low affinity site on the opposite side of the tunnel (PDB: 3F6K).


## SORTILIN IS ASSOCIATED TO DISTINCTS NTSRs TO MODULATE NT-MEDIATED ENDOCRINE CELL FUNCTIONS

Physiological studies performed during the first years following the discovery of NT in 1973, revealed some interesting results concerning the potential involvement of the peptide in glucose homeostasis and lipid absorption. Indeed in human, NT is released in the blood circulation after a meal, and lipid absorption stimulates NT release from the rat small intestine (Leeman and Carraway, 1982). In addition, NT is released from pancreas in STZ-diabetic rats (Berelowitz and Frohman, 1982) and is co-localized with glucagon in the endocrine human fetal pancreas (Portela-Gomes et al., 1999). Interestingly, NT exerts a dual effect on the rat endocrine pancreas: at low glucose concentration, the peptide stimulates insulin and glucagon release whereas at high glucose concentration, it has the opposite effect (Dolais-Kitabgi et al., 1979). Furthermore, NT administration increases pancreatic weight and DNA content indicating a prominent proliferative effect of the peptide on pancreatic cells (Feurle et al., 1987; Wood et al., 1988).

As involvement of NT in glucose homeostasis become clearer, understanding the mechanisms of its action on insulin-secreting cells is crucial, especially because RT-PCR and Western blot analyses have demonstrated that all NTSRs are expressed in rat and mouse islets and in insulin-secreting beta cell lines (Coppola et al., 2008; Beraud-Dufour et al., 2009). Functionally, NT can modulate various biological responses both in insulinoma derived cell lines and in isolated pancreatic islets (Khan et al., 2017; **Figure 2**) suggesting the possibility of differential activation pathways by NT. In this area, some studies indicated that the PKC proteins play a key role in the direct effect of NT on insulin secretion from beta cells (Beraud-Dufour et al., 2010; Khan et al., 2017).

Clinical data, by showing that circulating NT levels are increased in human diabetes and obesity (Melander et al., 2012; Chowdhury et al., 2016) identified NT regulation as a promising therapeutic target in these most prevalent and challenging health conditions. This was correlated by *in vivo* studies showing that NT (NT<sup>-/-</sup>) and sortilin KO mice (Sort1<sup>-/-</sup>) share some common phenotypes, especially by protecting from obesity, hepatic steatosis, and metabolic disorders. Indeed, sortilin deficiency induces a beneficial metabolic phenotype in liver and adipose tissue against high fat diet (Rabinowich et al., 2015).

Furthermore, studies on double knockout mice for the low-density lipoprotein receptor (Ldlr<sup>-/-</sup>, an atherosclerosis



model) and sortilin (Sort1<sup>-/-</sup>) have confirmed the previous observations showing that sortilin is crucial for lipid homeostasis by suppressing intestinal cholesterol absorption mostly in female mice (Hagita et al., 2018). It is important to note that some contradictory results were obtained using another so-called sort1<sup>-/-</sup> model (Li et al., 2017a). It was observed that suppression of sortilin gene does not affect diet-induced obesity and glucose uptake from adipose tissue and skeletal muscle. A closer look of both Sort1<sup>-/-</sup> model mice used showed that the first studies were performed using a mouse in which the exon 14th of the sortilin gene was deleted, leading to the expression of a soluble sortilin receptor (Rabinowich et al., 2015; Hagita et al., 2018).

The other deletion was done on the second exon deleting almost all of the sortilin protein (Li et al., 2017a). Similarly to the first Sort1<sup>-/-</sup> model described (Rabinowich et al., 2015; Hagita et al., 2018), NT-deficient mice are resistant to DIO, hepatic steatosis and insulin resistance (Li et al., 2016). In order to explain such differences between sortilin deficient mice models, it is possible to argue that the expression of a circulating soluble form of the receptor, is able to buffer the NT in the blood stream and also potentially the other sortilin-interacting peptides (Quistgaard et al., 2014). Thus, we can postulate that the truncated receptor depletes circulating NT, similarly to a NT KO- phenotype. In addition, the metabolic improved phenotype (protection from obesity, hepatic steatosis, and insulin resistance) observed in NT-deficiency suggests an involvement of sortilin in NT-regulation of glucose homeostasis.

In correlation with this postulate, it has been shown that NT has a potent anti-apoptotic effect against IL-1 $\beta$  or staurosporine (Coppola et al., 2008). This protective effect of NT is mediated by sortilin in combination with NTSR2 (Beraud-Dufour et al., 2009). Sortilin as a co-receptor with NTSR2 is necessary for the anti-apoptotic NT function and also for the peptide modulation of insulin secretion (Beraud-Dufour et al., 2010). This receptor heterodimer exerts a protective effect against apoptosis by stimulating PI-3 kinase activity which in turn phosphorylates Akt (Coppola et al., 2008). Importantly, recent works performed in rodent and human beta cells, showed that NT was also produced inside the islets and regulates adaptation to environmental stress (Khan et al., 2017).

These results, all together, underline that sortilin, as receptor or co-receptor for NT, may have a dual and beneficial role: protecting endocrine cells from stress induced apoptosis and/or controlling lipid absorption from the intestine.

## SORTILIN, A SORTING PROTEIN FOR GLUCOSE TRANSPORTER GLUT4, IS A KEY MODULATOR OF METABOLISM

As largely documented, sortilin and the glucose transporter GLUT4 are co-expressed in differentiated adipocytes and myotubes (Figure 1; Bogan and Kandror, 2010), and are necessary for glucose storage. Fine-tuning of the expression level



of both proteins is crucial in order to maintain insulin mediated glucose transport inside the cells (**Figure 2**). For example, formation of Glut4 storage vesicles in adipocytes and skeletal muscle cells correlates with the expression of sortilin (Ariga et al., 2008; Shi et al., 2008; Ariga et al., 2017). In addition, insulin dependent translocation of Glut4 is clearly correlated with the presence of sortilin in adipocytes (Huang et al., 2013). It has been hypothesized that defect in peripheral glucose transport, related to insulin resistance observed in obesity and diabetes, could be correlated *in vivo*, with modification of the expression level of sortilin (Kaddai et al., 2009).

In addition, sortilin expression is decreased in several physiopathological conditions such as obesity and this repression is TNF-alpha dependent. Interestingly, a link between chronic low-grade inflammation, sortilin expression and insulin resistance has been postulated (Kaddai et al., 2009). Indeed, sortilin expression is differently altered in insulin resistance models induced by TNF-alpha or dexamethasone treatments. In presence of TNF-alpha the expression of sortilin is drastically decreased and can be associated with insulin resistance; on the opposite dexamethasone dependent insulin resistance is not accompanied by sortilin downregulation (Hivelin et al., 2017; Li et al., 2017b). TNF-alpha combined with hypoxia was most able to mimic *in vivo* DIO-induced adipose insulin resistance (Lo et al., 2013). Also, sortilin gene expression is decreased in white adipose tissue of obese mice when PI3K/AKT signaling is inhibited (Li et al., 2017b).

TNF-alpha and dexamethasone are inducers of insulin resistance, respectively inhibiting insulin receptor tyrosine kinase activity (Hotamisligil et al., 1996; Rui et al., 2001) or inducing whole body insulin resistance without affecting GLUT4 translocation machinery (Qi et al., 2004). All together these results show that down regulation of sortilin expression may be one of the events leading to insulin resistance.

## **SORTILIN, ACTING ON TREK-1 CHANNEL, REGULATES CELL EXCITABILITY**

With respect to insulin resistance and secretion, potassium permeability by controlling the beta cell membrane potential regulates insulin secretion. Indeed, insulin granule exocytosis is induced by membrane depolarization that is a direct consequence of the inhibition of ATP dependent potassium channels by the increased ATP production from glucose metabolism. Other types of K<sup>+</sup> channels including TREK-1, a two-pore-domain (K<sub>2</sub>P) background potassium channel are known to be involved in the control of the resting membrane potential and the regulation of depolarizing stimulus (Kim and Kang, 2015).

This is part of the K<sub>2</sub>P(s) general properties. Background K<sup>+</sup> outward currents could adjust the membrane potential, low hyperpolarization or depolarization (Kim, 2005). Therefore, interfering with TREK-1 plasma conductance could play an important role in the electrophysiology of insulin secretion. TREK-1 channel could be thereby, a potential target for pharmacological agents designed to modulate this secretion. This

has to be underlined, as we have recently reported that the TREK-1 channel is inhibited by SDP (propeptide: Gln1-Arg44), as well as by its shorter analog spadin (Mazella et al., 2010).

Since structure function studies determined that SDP region Gln17-Arg28 was as efficient in binding affinity (K<sub>d</sub>~5nM) than the entire peptide, we generated a TREK-1 inhibitory peptide called spadin (Sortilin Peptide AntiDepressive in) which has amino acids 17–28 preceded by sequence 12–16 (APLRP) to maintain conformational stress (Mazella et al., 2010). Results clearly demonstrated the capacity of spadin and SDP for blocking TREK-1 currents (Mazella et al., 2010). The bioactivity of SDP is of interest as a specific SDP dosing assay revealed that its circulating level is of significant concentrations (10 nM) in the mouse serum (Mazella et al., 2010). In addition, TREK-1 and sortilin are co-expressed in pancreatic islets, only in  $\alpha$  and  $\beta$  cells. At a cellular level TREK-1 and sortilin co-localize in intracellular compartments (Hivelin et al., 2016). Therefore we explored the inhibitory effects of spadin on endogenous TREK-1 current in  $\beta$  pancreatic cells (Hivelin et al., 2016). We could observe changes in resting membrane potential in MIN6B1 pancreatic beta cell line incubated in the presence of 10nM spadin. The mild depolarization observed ( $\Delta$  = 12.84 mV), although not sufficient to induce insulin secretion by itself, potentiates the effect of secretagogues such as 16.7 mM glucose or 30 mM KCl (Hivelin et al., 2016). This PM depolarization likely facilitates the exocytosis process through the enhancement of intracellular calcium concentration. Moreover, we reported that during *in vivo* IPGTT experiments, glucose level is always lower in mice treated with spadin, suggesting a direct action of spadin on glycaemia (Hivelin et al., 2016).

Interestingly most of the consequences of spadin inhibitory action on TREK-1 channel were primarily documented in neurons, and among them some interesting features could be relevant for beta cell mass retention. Spadin as specific inhibitor for TREK-1 channel currents induces survival pathways, such as Akt and Erk pathways in primary cultured neurons (Devader et al., 2015). Accordingly, this was associated with an anti-apoptotic effect, associated with an increase of the phosphorylation of CREB. *In vivo*, spadin induces a rapid onset of neurogenesis (Mazella et al., 2010). Therefore, it is tempting to postulate that such protective and modulation of the proliferation pathways (Abdelli et al., 2009; Beeler et al., 2009), could be observed in endocrine pancreatic cells that share common traits with neurons. These traits are required for insulin secretion (Abderrahmani et al., 2004a,b).

## **SORTILIN AND proNGF PARTNERS IN DEATH FATE: SORTILIN DEPENDENT APOPTOSIS**

Since several years, a link between NGF and diabetes has been showed. For example, the NGF/proNGF expression ratio is decreased in the brain of diabetic rats (Soligo et al., 2015) and in STZ-induced diabetic rats (Sposato et al., 2007). Furthermore, these rats present an up-regulation of the p75NTR expression in the pancreas (Sposato et al., 2007), suggesting a role of this

receptor in the higher apoptosis rate observed in the endocrine pancreas of these animals. The role of the sortilin/p75NTR receptor complex in the induction of death described in neurons (Nykjaer et al., 2004) has also been identified in lymphocytes (Rogers et al., 2010). It has been demonstrated that proNGF, when TrkA expression decreases, switches PC12 cells from growth to apoptosis (Ioannou and Fahnestock, 2017). Interestingly, NGF receptors (p75NTR and TrkA) are expressed in human and rodent pancreatic islets (Miralles et al., 1998; Rosenbaum et al., 1998; Pingitore et al., 2016) and NGF is expressed and secreted by adult beta cells, suggesting an autocrine effect (Rosenbaum et al., 1998). Thus, it is tempting to postulate that a decreased maturation of proNGF, as observed in the brain of diabetic rat (Soligo et al., 2015), could represent a major cause of beta cell apoptosis. In that perspective, it would be of great importance to carefully analyze the role of sortilin, TrkA, p75NTR, and NGF as pro- or anti-apoptotic promoters in beta cells.

## CONCLUSION/PERSPECTIVES

The reviewing of the literature undoubtedly identifies the high affinity NT receptor, sortilin, as involved in key regulatory mechanisms of glucose homeostasis. Although it is generally accepted that the results obtained on cells from Langerhans islets are preferable to any other, most of the data showing a specific role of sortilin in beta cell comes from tumor-derived cell lines. Nevertheless, work on tumor lines, that retain much of the properties of differentiated cells (Merglen et al., 2004) is useful in understanding the role of sortilin. We cannot, at this stage, give a complete and perfectly defined role for sortilin in beta cell. However, it is possible to say, with caution, that sortilin could play a role in survival and function maintenance of beta cell, when associated with an NT receptor, or pro-apoptotic role when associated with p75NTR (Figure 2). These seemingly contradictory functions are not informed so far by *in vivo* studies emphasizing the usefulness of work on the endocrine pancreas of sort<sup>-/-</sup> mice.

## REFERENCES

- Abdelli, S., Puyal, J., Biemann, C., Buchillier, V., Abderrahmani, A., Clarke, P. G., et al. (2009). JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis. *Diabetologia* 52, 1871–1880. doi: 10.1007/s00125-009-1431-7
- Abderrahmani, A., Niederhauser, G., Plaisance, V., Haefliger, J. A., Regazzi, R., and Waeber, G. (2004a). Neuronal traits are required for glucose-induced insulin secretion. *FEBS Lett.* 565, 133–138.
- Abderrahmani, A., Niederhauser, G., Plaisance, V., Roehrich, M. E., Lenain, V., Coppola, T., et al. (2004b). Complexin I regulates glucose-induced secretion in pancreatic beta-cells. *J. Cell Sci.* 117, 2239–2247.
- Ariga, M., Nedachi, T., Katagiri, H., and Kanzaki, M. (2008). Functional role of sortilin in myogenesis and development of insulin-responsive glucose transport system in C2C12 myocytes. *J. Biol. Chem.* 283, 10208–10220. doi: 10.1074/jbc.M710604200
- Ariga, M., Yoneyama, Y., Fukushima, T., Ishiuchi, Y., Ishii, T., Sato, H., et al. (2017). Glucose deprivation attenuates sortilin levels in skeletal muscle cells. *Endocr. J.* 64, 255–268. doi: 10.1507/endocrj.EJ16-0319
- Arnett, M. G., Ryals, J. M., and Wright, D. E. (2007). Pro-NGF, sortilin, and p75NTR: potential mediators of injury-induced apoptosis in the mouse dorsal root ganglion. *Brain Res.* 1183, 32–42. doi: 10.1016/j.brainres.2007.09.051
- Beeler, N., Riederer, B. M., Waeber, G., and Abderrahmani, A. (2009). Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. *Brain Res. Bull.* 80, 274–281. doi: 10.1016/j.brainresbull.2009.07.006
- Beraud-Dufour, S., Abderrahmani, A., Noel, J., Brau, F., Waeber, G., Mazella, J., et al. (2010). Neurotensin is a regulator of insulin secretion in pancreatic beta-cells. *Int. J. Biochem. Cell Biol.* 42, 1681–1688. doi: 10.1016/j.biocel.2010.06.018
- Beraud-Dufour, S., Coppola, T., Massa, F., and Mazella, J. (2009). Neurotensin receptor-2 and -3 are crucial for the anti-apoptotic effect of neurotensin on pancreatic beta-TC3 cells. *Int. J. Biochem. Cell Biol.* 41, 2398–2402. doi: 10.1016/j.biocel.2009.04.002
- Berelowitz, M., and Frohman, L. A. (1982). The role of neurotensin in the regulation of carbohydrate metabolism and in diabetes. *Ann. N. Y. Acad. Sci.* 400, 150–159. doi: 10.1111/j.1749-6632.1982.tb31566.x
- Bogan, J. S., and Kandror, K. V. (2010). Biogenesis and regulation of insulin-responsive vesicles containing GLUT4. *Curr. Opin. Cell Biol.* 22, 506–512. doi: 10.1016/j.celb.2010.03.012

## AUTHOR CONTRIBUTIONS

NB and SB-D shared first co-authorship. All authors participated in writing the article.

## FUNDING

This work was supported by the Centre National de la Recherche Scientifique, a grant from the Société Francophone du Diabète (SFD 2011) to TC.

## ACKNOWLEDGMENTS

We thank Franck Aguila for art work. We thank all their past and present team members and collaborators who have contributed to the data discussed in the review. We are grateful to Dr. Catherine Heurteaux and Dr. Romain Gautier for helpful discussions. We also thank the French Government for the “Investments for the Future” LABEX ICST # ANR-11 LABX 0015.

- Chowdhury, S., Wang, S., Dunai, J., Kilpatrick, R., Oestricher, L. Z., Wallendorf, M. J., et al. (2016). Hormonal responses to cholinergic input are different in humans with and without type 2 diabetes mellitus. *PLoS One* 11:e0156852. doi: 10.1371/journal.pone.0156852
- Coppola, T., Beraud-Dufour, S., Antoine, A., Vincent, J. P., and Mazella, J. (2008). Neurotensin protects pancreatic beta cells from apoptosis. *Int. J. Biochem. Cell Biol.* 40, 2296–2302. doi: 10.1016/j.biocel.2008.03.015
- Devader, C., Khayachi, A., Veyssiere, J., Moha Ou Maati, H., Roulot, M., Moreno, S., et al. (2015). In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin. *Br. J. Pharmacol.* 172, 2604–2617. doi: 10.1111/bph.13083
- Dolais-Kitabgi, J., Kitabgi, P., Brazeau, P., and Freychet, P. (1979). Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets. *Endocrinology* 105, 256–260. doi: 10.1210/endo-105-1-256
- Feurle, G. E., Muller, B., and Rix, E. (1987). Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. *Gut* 28(Suppl.), 19–23. doi: 10.1136/gut.28.Suppl.19
- Hagita, S., Rogers, M. A., Pham, T., Wen, J. R., Mlynarchik, A. K., Aikawa, M., et al. (2018). Transcriptional control of intestinal cholesterol absorption, adipose energy expenditure and lipid handling by sortilin. *Sci. Rep.* 8:9006. doi: 10.1038/s41598-018-27416-y
- Hermans-Borgmeyer, I., Hermey, G., Nykjaer, A., and Schaller, C. (1999). Expression of the 100-kDa neurotensin receptor sortilin during mouse embryonal development. *Brain Res. Mol. Brain Res.* 65, 216–219. doi: 10.1016/S0169-328X(99)00022-4
- Hermey, G., Riedel, I. B., Hampe, W., Schaller, H. C., and Hermans-Borgmeyer, I. (1999). Identification and characterization of SorCS, a third member of a novel receptor family. *Biochem. Biophys. Res. Commun.* 266, 347–351. doi: 10.1006/bbrc.1999.1822
- Hivelin, C., Beraud-Dufour, S., Devader, C., Abderrahmani, A., Moreno, S., Moha Ou Maati, H., et al. (2016). Potentiation of calcium influx and insulin secretion in pancreatic beta cell by the specific TREK-1 blocker spadin. *J. Diabetes Res.* 2016, 1–9. doi: 10.1155/2016/3142175
- Hivelin, C., Mazella, J., and Coppola, T. (2017). Sortilin derived propeptide regulation during adipocyte differentiation and inflammation. *Biochem. Biophys. Res. Commun.* 482, 87–92. doi: 10.1016/j.bbrc.2016.10.139
- Hotamisligil, G. S., Johnson, R. S., Distel, R. J., Ellis, R., Papaioannou, V. E., and Spiegelman, B. M. (1996). Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. *Science* 274, 1377–1379. doi: 10.1126/science.274.5291.1377
- Huang, G., Buckler-Pena, D., Nauta, T., Singh, M., Asmar, A., Shi, J., et al. (2013). Insulin responsiveness of glucose transporter 4 in 3T3-L1 cells depends on the presence of sortilin. *Mol. Biol. Cell* 24, 3115–3122. doi: 10.1091/mbc.E12-10-0765
- Ioannou, M. S., and Fahnestock, M. (2017). ProNGF, but Not NGF, switches from neurotrophic to apoptotic activity in response to reductions in TrkA receptor levels. *Int. J. Mol. Sci.* 18:E599. doi: 10.3390/ijms18030599
- Jacobsen, L., Madsen, P., Moestrup, S. K., Lund, A. H., Tommerup, N., Nykjaer, A., et al. (1996). Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. *J. Biol. Chem.* 271, 31379–31383. doi: 10.1074/jbc.271.49.31379
- Kaddai, V., Jager, J., Gonzalez, T., Najem-Lendom, R., Bonnafous, S., Tran, A., et al. (2009). Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. *Diabetologia* 52, 932–940. doi: 10.1007/s00125-009-1273-3
- Khan, D., Vasu, S., Moffett, R. C., Gault, V. A., Flatt, P. R., and Irwin, N. (2017). Locally produced xenin and the neurotensinergic system in pancreatic islet function and beta-cell survival. *Biol. Chem.* 399, 79–92. doi: 10.1515/hsz-2017-0136
- Kim, D. (2005). Physiology and pharmacology of two-pore domain potassium channels. *Curr. Pharm. Des.* 11, 2717–2736. doi: 10.2174/1381612054546824
- Kim, D., and Kang, D. (2015). Role of K<sub>2</sub>p channels in stimulus-secretion coupling. *Pflugers Arch.* 467, 1001–1011. doi: 10.1007/s00424-014-1663-3
- Leeman, S. E., and Carraway, R. E. (1982). Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. *Ann. N. Y. Acad. Sci.* 400, 1–16. doi: 10.1111/j.1749-6632.1982.tb31557.x
- Li, J., Matye, D. J., Wang, Y., and Li, T. (2017a). Sortilin 1 knockout alters basal adipose glucose metabolism but not diet-induced obesity in mice. *FEBS Lett.* 591, 1018–1028. doi: 10.1002/1873-3468.12610
- Li, J., Wang, Y., Matye, D. J., Chavan, H., Krishnamurthy, P., Li, F., et al. (2017b). Sortilin 1 modulates hepatic cholesterol lipotoxicity in mice via functional interaction with liver carboxylesterase 1. *J. Biol. Chem.* 292, 146–160. doi: 10.1074/jbc.M116.762005
- Li, J., Song, J., Zaytseva, Y. Y., Liu, Y., Rychahou, P., Jiang, K., et al. (2016). An obligatory role for neurotensin in high-fat-diet-induced obesity. *Nature* 533, 411–415. doi: 10.1038/nature17662
- Lo, K. A., Labadorf, A., Kennedy, N. J., Han, M. S., Yap, Y. S., Matthews, B., et al. (2013). Analysis of in vitro insulin-resistance models and their physiological relevance to in vivo diet-induced adipose insulin resistance. *Cell Rep.* 5, 259–270. doi: 10.1016/j.celrep.2013.08.039
- Mazella, J., Chabry, J., Zsurgur, N., and Vincent, J. P. (1989). Purification of the neurotensin receptor from mouse brain by affinity chromatography. *J. Biol. Chem.* 264, 5559–5563.
- Mazella, J., Petraut, O., Lucas, G., Deval, E., Beraud-Dufour, S., Gandin, C., et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. *PLoS Biol.* 8:e1000355. doi: 10.1371/journal.pbio.1000355
- Mazella, J., Zsurgur, N., Navarro, V., Chabry, J., Kaghad, M., Caput, D., et al. (1998). The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. *J. Biol. Chem.* 273, 26273–26276. doi: 10.1074/jbc.273.41.26273
- Melander, O., Maisel, A. S., Almgren, P., Manjer, J., Belting, M., Hedblad, B., et al. (2012). Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. *JAMA* 308, 1469–1475. doi: 10.1001/jama.2012.12998
- Merglen, A., Theander, S., Rubi, B., Chaffard, G., Wollheim, C. B., and Maechler, P. (2004). Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. *Endocrinology* 145, 667–678. doi: 10.1210/en.2003-1099
- Miralles, F., Philippe, P., Czernichow, P., and Scharfmann, R. (1998). Expression of nerve growth factor and its high-affinity receptor Trk-A in the rat pancreas during embryonic and fetal life. *J. Endocrinol.* 156, 431–439. doi: 10.1677/joe.0.1560431
- Morris, N. J., Ross, S. A., Lane, W. S., Moestrup, S. K., Petersen, C. M., Keller, S. R., et al. (1998). Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes. *J. Biol. Chem.* 273, 3582–3587. doi: 10.1074/jbc.273.6.3582
- Munck Petersen, C., Nielsen, M. S., Jacobsen, C., Tauris, J., Jacobsen, L., Gliemann, J., et al. (1999). Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. *EMBO J.* 18, 595–604. doi: 10.1093/emboj/18.3.595
- Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., et al. (2004). Sortilin is essential for proNGF-induced neuronal cell death. *Nature* 427, 843–848. doi: 10.1038/nature02319
- Petersen, C. M., Ellgaard, L., Nykjaer, A., Vilhardt, F., Vorum, H., Thøgersen, H. C., et al. (1996). The receptor-associated protein (RAP) binds calmodulin and is phosphorylated by calmodulin-dependent kinase II. *EMBO J.* 15, 4165–4173. doi: 10.1002/j.1460-2075.1996.tb00791.x
- Petersen, C. M., Nielsen, M. S., Nykjaer, A., Jacobsen, L., Tommerup, N., Rasmussen, H. H., et al. (1997). Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. *J. Biol. Chem.* 272, 3599–3605.
- Pingitore, A., Caroleo, M. C., Cione, E., Castanera Gonzalez, R., Huang, G. C., and Persaud, S. J. (2016). Fine tuning of insulin secretion by release of nerve growth factor from mouse and human islet beta-cells. *Mol. Cell. Endocrinol.* 436, 23–32. doi: 10.1016/j.mce.2016.07.014
- Portela-Gomes, G. M., Johansson, H., Olding, L., and Grimelius, L. (1999). Co-localization of neuroendocrine hormones in the human fetal pancreas. *Eur. J. Endocrinol.* 141, 526–533. doi: 10.1530/eje.0.1410526
- Qi, D., Pulinilkunnil, T., An, D., Ghosh, S., Abrahani, A., Pospisilik, J. A., et al. (2004). Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. *Diabetes Metab. Res. Rev.* 53, 1790–1797. doi: 10.2337/diabetes.53.7.1790
- Quistgaard, E. M., Groftehauge, M. K., Madsen, P., Pallesen, L. T., Christensen, B., Sørensen, E. S., et al. (2014). Revisiting the structure of the Vps10 domain of

- human sortilin and its interaction with neurotensin. *Protein Sci.* 23, 1291–1300. doi: 10.1002/pro.2512
- Quistgaard, E. M., Madsen, P., Groftehauge, M. K., Nissen, P., Petersen, C. M., and Thirup, S. S. (2009). Ligands bind to sortilin in the tunnel of a ten-bladed beta-propeller domain. *Nat. Struct. Mol. Biol.* 16, 96–98. doi: 10.1038/nsmb.1543
- Rabinowich, L., Fishman, S., Hubel, E., Thurm, T., Park, W. J., Pewzner-Jung, Y., et al. (2015). Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. *J. Hepatol.* 62, 175–181. doi: 10.1016/j.jhep.2014.08.030
- Rogers, M. L., Bailey, S., Matusica, D., Nicholson, I., Muyderman, H., Pagadala, P. C., et al. (2010). ProNGF mediates death of natural killer cells through activation of the p75NTR-sortilin complex. *J. Neuroimmunol.* 226, 93–103. doi: 10.1016/j.jneuroim.2010.05.040
- Rosenbaum, T., Vidaltamayo, R., Sanchez-Soto, M. C., Zentella, A., and Hiriart, M. (1998). Pancreatic beta cells synthesize and secrete nerve growth factor. *Proc. Natl. Acad. Sci. U.S.A.* 95, 7784–7788. doi: 10.1073/pnas.95.13.7784
- Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I., Lee, A., Corbould, A., et al. (2001). Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. *J. Clin. Invest.* 107, 181–189. doi: 10.1172/JCI10934
- Shi, J., Huang, G., and Kandror, K. V. (2008). Self-assembly of Glut4 storage vesicles during differentiation of 3T3-L1 adipocytes. *J. Biol. Chem.* 283, 30311–30321. doi: 10.1074/jbc.M805182200
- Soligo, M., Protto, V., Florenzano, F., Bracci-Laudiero, L., De Benedetti, F., Chiaretti, A., et al. (2015). The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: analysis by ELISA methods. *Brain Res.* 1624, 455–468. doi: 10.1016/j.brainres.2015.08.005
- Sposato, V., Manni, L., Chaldakov, G. N., and Aloe, L. (2007). Streptozotocin-induced diabetes is associated with changes in NGF levels in pancreas and brain. *Arch. Ital. Biol.* 145, 87–97.
- Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. *J. Neurosci.* 25, 5455–5463. doi: 10.1523/JNEUROSCI.5123-04.2005
- Wood, J. G., Hoang, H. D., Bussjaeger, L. J., and Solomon, T. E. (1988). Effect of neurotensin on pancreatic and gastric secretion and growth in rats. *Pancreas* 3, 332–339. doi: 10.1097/00006676-198805000-00015

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Blondeau, Béraud-Dufour, Lebrun, Hivelin and Coppola. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.